Senzime
UPPSALA, SE / ACCESSWIRE / November 30, 2023 // Senzime (STO:SEZI) Senzime, an industry leader in algorithm-based patient monitoring solutions, today announced that it has secured multiple new orders for the TetraGraph system from several German university hospitals. The orders are the result of comprehensive clinical and competitive product evaluations. When fully deployed, these hospitals are expected to generate annual recurring revenue contributing significantly to announced financial targets.
"We continue to demonstrate that we are the trusted vendor of choice for leading hospitals that are starting to operate in the spirit of the new clinical guidelines of objective neuromuscular monitoring on patients receiving neuromuscular blocking drugs. Since our introduction on the German market in early 2021, our sales team has secured nearly 30 major hospital contracts including several key robotic surgery centers. These new orders are important milestones for us and indicators that the new European clinical guidelines are getting implemented in clinical practice", comments Philip Siberg, CEO of Senzime.
TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and that meets the new clinical guidelines published by ESAIC (European Society of Anaesthesiology and Intensive Care) and the ASA (American Society of Anesthesiologists).
The TetraGraph system is used during surgery to accurately monitor the patient's level of neuromuscular block. This helps anesthesiologists secure the right dose of neuromuscular blocking drugs and their antagonists during surgery, as well as indicate when it is safe to allow patients to breathe again on their own.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Attachments
Senzime secures multiple university hospital orders in Germany
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.SOURCE: Senzime
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release
IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
Atha Energy Identifies Numerous Outcrops Hosting High-Grade Uranium Mineralization5.12.2024 07:00:00 CET | Press release
HIGHLIGHTS Surficial mapping was conducted as part of the 2024 Angilak Exploration Program that focused on areas strictly proximal to the Lac 50 Deposit and achieved its objective of discovering high-grade uranium mineralization on surface beyond the extents of the Lac 50 Deposit's Exploration Target Model; High-grade surficial uranium mineralization was identified between Lac 48, Lac 50, Lac 52, and Lac 54 trends, collectively known as the Lac 50 Deposit, along prospective new parallel trends; Discovery of outlined outcrops containing high-grade uranium mineralization along strike from the Lac 50 Deposit provide basis for future exploration and significantly de-risk expansion efforts; A zone of extensive bedrock outcrop with radioactivity up to >60,000 counts per second (cps) - >10,000 cps is indicative of high-grade uranium mineralization - was identified over a 3-kilometre strike length. The new discovery is located between the Mushroom Lake zone on the Lac 52 trend and the Hot zone
TACACS.net: Strengthening Network Security with Native Active Directory Integration4.12.2024 16:55:00 CET | Press release
The Weakest Link in Cybersecurity: Addressing Authentication Vulnerabilities SAN JOSE, CA / ACCESSWIRE / December 4, 2024 / In an era where 75% of security breaches are attributed to weak authentication, the importance of robust cybersecurity measures has never been greater. Recognizing this critical need, TACACS.net has emerged as the #1 choice for Active Directory (AD) integration, offering unmatched reliability, performance, and security. Authentication is often the weakest link in network security. If a hacker cannot authenticate to a device, they cannot exploit it. TACACS.net addresses this vulnerability by delivering a solution built to meet the needs of modern organizations, ensuring fast, secure, and seamless integration with existing infrastructure. Why TACACS.net Stands Out Most organizations rely on Active Directory to manage users, but competing solutions depend on middleware-complex intermediaries that often fail, usually at the worst possible time. TACACS.net is the only
Polaris Renewable Energy Successfully Settles USD 175 Million Bond Issue4.12.2024 16:05:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 4, 2024 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announces that it has successfully settled a previously announced private placement of USD 175 million senior secured green bonds. The bonds will have a tenor of five years and a fixed coupon rate of 9.5% percent per annum, with interest payable in semi-annual instalments. Furthermore, the Green Bond will include a tap feature, allowing for access to an additional USD $50 million in funding for potential future uses. The bond issue is rated BB- by S&P Global Ratings and is issued under the Company's green finance framework with second-party opinion from Morningstar Sustainalytics. Marc Murnaghan, Chief Executive Officer of Polaris comments: "We are very pleased to successfully settle this inaugural bond issue with strong interest from a wide set of international investors. The bond optimizes the Company's capital structure and secures financing for further growth and incre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom